TY - JOUR
T1 - Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are diagnosed with non-Hodgkin lymphoma
T2 - population-based analyses from the state of Georgia
AU - Lipscomb, Joseph
AU - Switchenko, Jeffrey M.
AU - Flowers, Christopher R.
AU - Gillespie, Theresa W.
AU - Wortley, Pascale M.
AU - Bayakly, A. Rana
AU - Almon, Lyn
AU - Ward, Kevin C.
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - For people living with HIV (PLWH) who are subsequently diagnosed with non-Hodgkin lymphoma (NHL), we investigate the impact of standard-of-care (SoC) cancer treatment on all-cause, NHL-specific, and HIV-specific survival outcomes. The focus is on a registry-derived, population-based sample of HIV + adults diagnosed with NHL within 2004–2012 in the state of Georgia. SoC treatment is defined as receipt of multi-agent systemic therapy (MAST). In multivariable survival analyses, SoC cancer treatment is significantly associated with better all-cause and NHL-specific survival, but not better HIV-specific survival across 2004–2017. Having a CD4 count <200 near the time of cancer diagnosis and Ann Arbor stage III/IV disease are associated with worse all-cause and HIV-specific survival; the effects on NHL survival trend negative but are not significant. Future work should expand the geographic base and cancers examined, deepen the level of clinical detail brought to bear, and incorporate the perspectives and recommendations of patients and providers.
AB - For people living with HIV (PLWH) who are subsequently diagnosed with non-Hodgkin lymphoma (NHL), we investigate the impact of standard-of-care (SoC) cancer treatment on all-cause, NHL-specific, and HIV-specific survival outcomes. The focus is on a registry-derived, population-based sample of HIV + adults diagnosed with NHL within 2004–2012 in the state of Georgia. SoC treatment is defined as receipt of multi-agent systemic therapy (MAST). In multivariable survival analyses, SoC cancer treatment is significantly associated with better all-cause and NHL-specific survival, but not better HIV-specific survival across 2004–2017. Having a CD4 count <200 near the time of cancer diagnosis and Ann Arbor stage III/IV disease are associated with worse all-cause and HIV-specific survival; the effects on NHL survival trend negative but are not significant. Future work should expand the geographic base and cancers examined, deepen the level of clinical detail brought to bear, and incorporate the perspectives and recommendations of patients and providers.
KW - competing risks
KW - HIV/AIDS
KW - Non-Hodgson lymphoma
KW - outcomes research
KW - standard-of-care therapy
KW - survival analysis
UR - http://www.scopus.com/inward/record.url?scp=85141198230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141198230&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2133539
DO - 10.1080/10428194.2022.2133539
M3 - Article
C2 - 36308021
AN - SCOPUS:85141198230
SN - 1042-8194
VL - 64
SP - 151
EP - 160
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -